JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
MRX
Marex Group plc Ordinary Shares
There isn't enough reported data to score MRX yet.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
MRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate MRX's fundamentals.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
MRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | N/A | N/A |
| Fair | 14x | N/A | N/A |
| Expensive | 17x | N/A | N/A |
| Current | 18x | $71.68 | — |
Historical ranges are pointers, not guarantees.
MRX's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
MRX Forward outlook
There aren't enough analyst estimates for MRX to show an outlook.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
MRX Earnings Per Share
MRX and JPM do not have enough comparable growth data to identify a winner.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
MRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2B | +306% |
| Q4 2025 | $3.1B | +45% |
| Q2 2025 | $500.1M | -32% |
| Q4 2024 | $2.2B | +199% |
| Q2 2024 | $740M | -36% |
| Q4 2023 | $720.7M | +109% |
| Q2 2023 | $1.2B | +75% |
| Q4 2022 | $345.3M | -16% |
MRX has the edge over JPM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 59% | +6.1 points |
| Q4 2025 | 34% | +50 points |
| Q2 2025 | 20% | +19 points |
| Q4 2024 | 20% | +2.2 points |
| Q2 2024 | 53% | +47 points |
| Q4 2023 | -16% | -25 points |
| Q2 2023 | 0.8% | -7.5 points |
| Q4 2022 | 18% | +13 points |
MRX has the edge over JPM on profitability, with a higher operating margin.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
MRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $692M | -25% |
| Q4 2025 | -$264.5M | -138% |
| Q2 2025 | $918.9M | +107% |
| Q4 2024 | $704.6M | +95% |
| Q2 2024 | $443.3M | +23% |
| Q4 2023 | $361.5M | +234% |
| Q2 2023 | $361.5M | +234% |
| Q4 2022 | $108.1M | -53% |
MRX's free cash flow was $2.1B over the past year, up 61% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MRX.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over MRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
MRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -487K shares |
| 1 year | +4.7% | +3.4M shares |
| 3 years | +25% | +15M shares |
MRX has 76M diluted shares, up 4.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $125.6M |
| Q4 2025 | $200,000 |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | $19.8M |
| Q4 2023 | $1.6M |
| Q2 2023 | $1.6M |
| Q4 2022 | $4M |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
MRX Net Leverage
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
MRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 40.9 | Neutral |
MRX's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over MRX on valuation relative to its sector.
MRX PE vs Financial Services Sector
| Metric | MRX | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 42% above |
| PE % | 93 | 29 | 64 pts above |
MRX is trading at 18x earnings, a 42% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
MRX has stronger trend alignment. JPM is above 4 of 5 weekly averages versus MRX above 4 of 4.
MRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $69.8 | 2.6% above |
| 20 week MA | $69.1 | 3.8% above |
| 50 week MA | $55.3 | 30% above |
| 100 week MA | $45.7 | 57% above |
MRX is in an uptrend: it's above all four of its weekly moving averages, and 57% above its 100-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
MRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.0 | $31.9 | +68% |
| 2025 | $31.9 | $39.6 | +24% |
| 2026 YTD | $39.6 | $71.7 | +81% |
MRX has the edge over JPM on returns for 2026, with the stronger performance.